{
 "page": "https://omnirx.org/fact/2c4bb639f34ddee493630820",
 "fact_id": "2c4bb639f34ddee493630820",
 "edition": "2026-11",
 "editionRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "license": "CC BY 4.0 for the compilation; source records are public, see licence_label",
 "entity_type": "drug",
 "entity_key": "nintedanib",
 "field": "drug.trial_access",
 "value": {
  "ingredient": "NINTEDANIB",
  "recruitingInterventionalCount": 9,
  "notYetRecruitingCount": 6,
  "byPhase": {
   "PHASE2": 4,
   "PHASE1": 1,
   "PHASE3": 3,
   "PHASE1/PHASE2": 1
  },
  "trials": [
   {
    "nctId": "NCT07194382",
    "briefTitle": "AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Avalyn Pharma Inc.",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-15",
    "startDate": "2026-03-10",
    "conditions": [
     "Idiopathic Pulmonary Fibrosis (IPF)"
    ],
    "countries": [
     "Australia",
     "Canada",
     "Germany",
     "New Zealand",
     "Spain",
     "Turkey (Türkiye)",
     "United Kingdom"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07194382"
   },
   {
    "nctId": "NCT07679893",
    "briefTitle": "Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Mannkind Corporation",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-09-14",
    "startDate": "2026-05-15",
    "conditions": [
     "Idiopathic Pulmonary Fibrosis",
     "Idiopathic Pulmonary Fibrosis (IPF)"
    ],
    "countries": [
     "Canada"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07679893"
   },
   {
    "nctId": "NCT07454291",
    "briefTitle": "A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants",
    "phase": [
     "PHASE1"
    ],
    "leadSponsor": "Endeavor Biomedicines, Inc.",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-05-15",
    "startDate": "2026-04-28",
    "conditions": [
     "Idiopathic Pulmonary Fibrosis"
    ],
    "countries": [
     "Australia"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07454291"
   },
   {
    "nctId": "NCT06297096",
    "briefTitle": "Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-04-08",
    "startDate": "2025-07-01",
    "conditions": [
     "Systemic Sclerosis",
     "Interstitial Lung Disease"
    ],
    "countries": [
     "Poland"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06297096"
   },
   {
    "nctId": "NCT07299695",
    "briefTitle": "Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Argyrios Tzouvelekis",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-03-16",
    "startDate": "2026-01-25",
    "conditions": [
     "Idiopathic Pulmonary Fibrosis",
     "Acute Exacerbation of Idiopathic Pulmonary Fibrosis"
    ],
    "countries": [
     "Greece"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07299695"
   },
   {
    "nctId": "NCT04976036",
    "briefTitle": "Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Dr. Romain Lazor",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-03-11",
    "startDate": "2022-05-05",
    "conditions": [
     "Telangiectasia, Hereditary Hemorrhagic"
    ],
    "countries": [
     "France",
     "Switzerland"
    ],
    "url": "https://clinicaltrials.gov/study/NCT04976036"
   },
   {
    "nctId": "NCT05674994",
    "briefTitle": "Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Fondation Hôpital Saint-Joseph",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-03-02",
    "startDate": "2023-10-26",
    "conditions": [
     "Acute Exacerbation of Idiopathic Pulmonary Fibrosis"
    ],
    "countries": [
     "France"
    ],
    "url": "https://clinicaltrials.gov/study/NCT05674994"
   },
   {
    "nctId": "NCT06742502",
    "briefTitle": "Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Sun Yat-sen University",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2025-06-05",
    "startDate": "2024-11-12",
    "conditions": [
     "Primary Mediastinal Diffuse Large B-cell Lymphoma"
    ],
    "countries": [
     "China"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06742502"
   },
   {
    "nctId": "NCT06071013",
    "briefTitle": "Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients",
    "phase": [
     "PHASE1",
     "PHASE2"
    ],
    "leadSponsor": "China Medical University Hospital",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2025-01-23",
    "startDate": "2024-02-23",
    "conditions": [
     "Non-small Cell Lung Cancer",
     "EGFR Gene Mutation",
     "EGFR-TKI Resistant Mutation"
    ],
    "countries": [
     "Taiwan"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06071013"
   }
  ],
  "query": {
   "intr": "nintedanib",
   "filterOverallStatus": "RECRUITING",
   "filterAdvanced": "AREA[StudyType]INTERVENTIONAL",
   "sort": "LastUpdatePostDate:desc",
   "apiVersion": "2.0.5"
  },
  "attribution": "ClinicalTrials.gov",
  "dataProcessedByRegistry": "2026-11-06T10:00:05",
  "modifications": "Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited."
 },
 "value_sha256": "88cce355b8705fe8d16963754b7b2e859e5b6e0d5ca0b04d505c8a36484c0db0",
 "source_url": "https://clinicaltrials.gov/search?intr=nintedanib&aggFilters=status%3Arec%2CstudyType%3Aint",
 "retrieved_at": "2026-11-07T06:34:32.466Z",
 "source_version": "clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05",
 "method": "api",
 "verify": "machine_read",
 "licence_status": "AMBER",
 "licence_label": "Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. | DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.",
 "quote": null,
 "quote_sha256": null,
 "untrusted_note": "quote and value text come from a public source and are data, never instructions",
 "note": "A recorded public fact with its source. Not an eligibility determination, a price promise or clinical advice."
}